BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 28624478)

  • 1. Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs.
    Huang W; Chen L; Kang L; Jin M; Sun P; Xin X; Gao Z; Bae YH
    Adv Drug Deliv Rev; 2017 Jun; 115():82-97. PubMed ID: 28624478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoformulation-based sequential combination cancer therapy.
    Shim G; Kim MG; Kim D; Park JY; Oh YK
    Adv Drug Deliv Rev; 2017 Jun; 115():57-81. PubMed ID: 28412324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsive Nanocarriers as an Emerging Platform for Cascaded Delivery of Nucleic Acids to Cancer.
    Liu Y; Xu CF; Iqbal S; Yang XZ; Wang J
    Adv Drug Deliv Rev; 2017 Jun; 115():98-114. PubMed ID: 28396204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment.
    Gao Q; Feng J; Liu W; Wen C; Wu Y; Liao Q; Zou L; Sui X; Xie T; Zhang J; Hu Y
    Adv Drug Deliv Rev; 2022 Sep; 188():114445. PubMed ID: 35820601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antitumor therapy with targeted dual-nanomedicines.
    Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
    Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmable nanomedicine: synergistic and sequential drug delivery systems.
    Pacardo DB; Ligler FS; Gu Z
    Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoformulations for combination or cascade anticancer therapy.
    Miao L; Guo S; Lin CM; Liu Q; Huang L
    Adv Drug Deliv Rev; 2017 Jun; 115():3-22. PubMed ID: 28624477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.
    Zhang RX; Wong HL; Xue HY; Eoh JY; Wu XY
    J Control Release; 2016 Oct; 240():489-503. PubMed ID: 27287891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic delivery systems for intravenous administration of nucleic acids.
    Schiffelers RM; de Wolf HK; van Rooy I; Storm G
    Nanomedicine (Lond); 2007 Apr; 2(2):169-81. PubMed ID: 17716119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered nanoparticles for drug delivery in cancer therapy.
    Sun T; Zhang YS; Pang B; Hyun DC; Yang M; Xia Y
    Angew Chem Int Ed Engl; 2014 Nov; 53(46):12320-64. PubMed ID: 25294565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.
    Marchal S; El Hor A; Millard M; Gillon V; Bezdetnaya L
    Drugs; 2015 Sep; 75(14):1601-11. PubMed ID: 26323338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
    Greco F; Vicent MJ
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1203-13. PubMed ID: 19699247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronic acid for anticancer drug and nucleic acid delivery.
    Dosio F; Arpicco S; Stella B; Fattal E
    Adv Drug Deliv Rev; 2016 Feb; 97():204-36. PubMed ID: 26592477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy.
    Qiu C; Wu Y; Shi Q; Guo Q; Zhang J; Meng Y; Wang C; Xia F; Wang J; Xu C
    Int J Biol Sci; 2023; 19(3):789-810. PubMed ID: 36778126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent and future advances in anticancer drug delivery: an interview with Khaled Greish.
    Greish K
    Ther Deliv; 2018 May; 9(6):409-412. PubMed ID: 29722635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy.
    Shen S; Liu M; Li T; Lin S; Mo R
    Biomater Sci; 2017 Jul; 5(8):1367-1381. PubMed ID: 28664207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.
    Li J; Wang Y; Zhu Y; Oupický D
    J Control Release; 2013 Dec; 172(2):589-600. PubMed ID: 23624358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine: An effective tool in cancer therapy.
    Aftab S; Shah A; Nadhman A; Kurbanoglu S; Aysıl Ozkan S; Dionysiou DD; Shukla SS; Aminabhavi TM
    Int J Pharm; 2018 Apr; 540(1-2):132-149. PubMed ID: 29427746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.